TL;DR
This paper introduces a novel multifunctional biosensor capable of simultaneously assessing both anti-cancer efficacy and cardiotoxicity of drugs in real-time. Using this biosensor, the researchers evaluated AC0010, a new EGFR-TKI, demonstrating its potent inhibition of EGFR-mutant NSCLC cells while also revealing its potential to impair cardiomyocyte function at low concentrations.
What Problem Does This Paper Address?
Non-small cell lung cancer (NSCLC) remains a significant global health challenge. While Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKIs) have revolutionized treatment, concerns about their cardiotoxicity have grown. AC0010, a promising third-generation EGFR-TKI, was developed to overcome resistance but its cardiotoxic potential was unknown. Traditional methods for evaluating drug efficacy and toxicity are often time-consuming, invasive, or lack the ability to assess multiple parameters simultaneously. This creates a need for advanced tools that can provide a comprehensive, real-time, and label-free evaluation of drug candidates, bridging the gap between preclinical screening and clinical application.
Methods
The core innovation presented is a multifunctional biosensor that integrates two key electrode types:
- Microelectrodes (MEs): Used to record extracellular field potentials (EFPs), which reflect the electrical activity of cardiomyocytes.
- Interdigitated Electrodes (IDEs): Employed for electrical cell-substrate impedance sensing (ECIS) to monitor cell viability and mechanical beating.
This dual-electrode design allows for the simultaneous, label-free, and real-time measurement of:
- Cell Viability: Assessed via impedance changes.
- Electrophysiological Activity: Measured as EFPs.
- Mechanical Beating: Detected through impedance signals, capturing contraction and relaxation dynamics.
The biosensor was fabricated using standard microfabrication techniques on a quartz glass wafer. For cardiotoxicity assessment, primary cardiomyocytes were cultured on the biosensor chip. For anti-cancer efficacy, NSCLC cell lines (NCI-H1975 and A549) and normal fibroblasts (HFF-1) were also cultured on the chip. The study also employed traditional CCK8 assays and live/dead staining to validate the biosensor's findings.
Datasets
The study utilized the following cell lines:
- NCI-H1975: An EGFR-mutant NSCLC cell line (L858R/T790M).
- A549: A wild-type EGFR NSCLC cell line.
- HFF-1: Normal human fibroblasts.
- Primary cardiomyocytes: Isolated from neonatal rats.
These cell lines were cultured and treated with AC0010 at various concentrations to evaluate drug efficacy and toxicity. No new benchmark datasets were introduced; rather, the biosensor was used to generate data that was compared to traditional assays.
Key Insights and Ideas
- Integrated Efficacy and Toxicity Assessment: The most significant insight is the successful demonstration of a single platform that can simultaneously evaluate both the desired anti-cancer effect and potential adverse cardiac effects of a drug. This is a crucial step towards more efficient and comprehensive drug development.
- AC0010 Selectivity: The study confirms AC0010's targeted action against EGFR-mutant NSCLC cells (NCI-H1975) while showing minimal impact on wild-type EGFR cells (A549) and normal cells (HFF-1 and cardiomyocytes) at effective anti-cancer doses.
- Early Cardiotoxicity Detection: The biosensor revealed that even at concentrations effective against cancer cells (10 µM), AC0010 can induce subtle but significant changes in cardiomyocyte electrophysiology and mechanical function within an hour.
- Diastolic Dysfunction as a Potential Mechanism: The observed decrease in diastole time (DT) and the DT/MB interval ratio suggests impaired relaxation of cardiomyocytes, which could be an early indicator of cardiotoxicity and potentially lead to more severe issues like arrhythmias.
- Biosensor as a Predictive Tool: The findings highlight the potential of this multifunctional biosensor to predict drug-induced cardiotoxicity earlier in the drug development pipeline, potentially reducing the number of drugs withdrawn due to safety concerns later on.
Key Results
- Anti-NSCLC Efficacy: AC0010 demonstrated a dose-dependent inhibition of NCI-H1975 cells with an IC50 of 5.15 µM. A549 cells showed weak inhibition, and HFF-1 cells were unaffected.
- Cardiomyocyte Viability: AC0010 showed negligible inhibition of cardiomyocyte viability at concentrations up to 10 µM. Significant toxicity was only observed at higher concentrations (33 µM and 100 µM).
- Electrophysiological Effects: At 10 µM, AC0010 caused a significant decrease in EFP amplitude and an initial decrease followed by an increase in EFP interval within 6 hours.
- Mechanical Beating Effects: Similarly, 10 µM AC0010 led to decreased MB amplitude and interval within 1 hour, with subsequent repression of action potential and beating.
- Diastolic Dysfunction: Analysis of systole time (ST) and diastole time (DT) revealed a significant decrease in DT within 1 hour of AC0010 treatment, suggesting insufficient relaxation.
Limitations and Future Work
- Mechanism Ambiguity: The paper acknowledges that the precise underlying mechanisms of AC0010-induced cardiotoxicity are not fully elucidated and are outside the scope of this study. Future work should focus on identifying these mechanisms.
- In Vitro Model: The study uses isolated cardiomyocytes and cell lines. While valuable, these in vitro models do not fully replicate the complex in vivo environment of the heart.
- Future Directions: The authors suggest further exploration of integrating bioelectronics with microfluidic channels for more advanced drug screening. They also propose adapting the biosensor for more complex and biomimetic cardiac models, such as 3D cardiac structures, spheroids, and organoids, to expand its application in pharmaceutical studies and preclinical testing.
Summary updated